title: Topical capsaicin in painful diabetic neuropathy. Controlled study with long-term follow-up.
abstract: OBJECTIVE
  We conducted an 8-wk controlled study with topical 0.075% capsaicin in subjects with chronic severe painful diabetic neuropathy who were unresponsive or intolerant to conventional therapy. Capsaicin is an alkaloid found in capsicum peppers and produces desensitization to noxious thermal, chemical, and mechanical stimuli when applied topically.
  
  
  METHODS
  In 22 randomly assigned subjects, either capsaicin or vehicle cream was applied to painful areas 4 times/day. Pain measurements were recorded at baseline and at 2-wk intervals for 8 wk.
  
  
  RESULTS
  Capsaicin treatment was more beneficial than vehicle treatment in the overall clinical improvement of pain status, as measured by physician's global evaluation (P = 0.038) and by a categorical pain severity scale (P = 0.057). Decrease in mean pain intensity by a visual analogue scale was 16% in capsaicin-treated and 4.1% in vehicle-treated subjects. Mean pain relief on visual analogue scale was 44.6 and 23.2%, respectively. In a follow-up open-label study, approximately 50% of subjects reported improved pain control or were cured, and 25% each were unchanged or worse. A burning sensation at the application site was noted by some subjects but both its magnitude and duration decreased with time.
  
  
  CONCLUSIONS
  Results from this preliminary study suggest that topical 0.075% capsaicin may be of value in subjects with diabetic neuropathy and intractable pain.
authors.affiliation: Department of Neurology, University of Vermont College of Medicine, Burlington.
authors.forename: R
authors.initials: R
authors.lastname: Tandan
authors.forename: G A
authors.initials: GA
authors.lastname: Lewis
authors.forename: P B
authors.initials: PB
authors.lastname: Krusinski
authors.forename: G B
authors.initials: GB
authors.lastname: Badger
authors.forename: T J
authors.initials: TJ
authors.lastname: Fries
mesh_terms: D000287:Administration, Topical; D002211:Capsaicin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D003929:Diabetic Neuropathies / Q000188:drug therapy / Q000503:physiopathology*; D004311:Double-Blind Method; D005260:Female; D005500:Follow-Up Studies; D006442:Glycated Hemoglobin / Q000032:analysis; D006801:Humans; D008297:Male; D008875:Middle Aged; D010148:Intractable Pain / Q000188:drug therapy* / Q000503:physiopathology
chemical_list: D002211:Capsaicin; D006442:Glycated Hemoglobin